5753 studies found for:    vaccines
Show Display Options
Rank Status Study
1 Completed
Has Results
The Immunogenicity and Safety of 60mcg/30mcg Recombinant Hepatitis B Vaccines in People Who Failed to Respond to Routine Administration of Hepatitis B Vaccines
Condition: Hepatitis b
Interventions: Biological: 60mcg/1.0ml recombinant hepatitis B vaccine;   Biological: 30mcg/1.0ml recombinant hepatitis B vaccine;   Biological: 10mcg/1.0ml recombinant hepatitis B vaccine
2 Completed
Has Results
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants
Condition: Meningitis, Meningococcal
Interventions: Biological: Meningococcal ACWY Conjugate Vaccine;   Biological: DTaP-IPV-HBV;   Biological: Hib;   Biological: Rotavirus;   Biological: Pneumococcal 7-valent Conjugate Vaccine;   Biological: HAV;   Biological: MMR-V;   Biological: DTaP
3 Completed School Influenza Vaccine vs Standard of Care With Nested Trial of 2 Parent Notification Intensities
Conditions: Immunizations;   Vaccination;   Influenza;   School Health
Interventions: Behavioral: School based flu vaccine: Low intensity;   Behavioral: School based flu vaccine: High intensity
4 Unknown  Conjugate And Polysaccharide Vaccines Compared With Polysaccharide Vaccine In Hiv-Infected Adults
Conditions: Pneumococcal Vaccines;   HIV;   HIV Infections
Intervention: Biological: Prevenar and Pneumo23
5 Completed Randomized Single-Blinded Study to Evaluate Safety and Immunogenicity of Recombinant Plague Vaccine With and Without Adjuvant
Condition: Plague Vaccine
Interventions: Biological: rF1V vaccine (with Adjuvant);   Biological: rF1V vaccine (without Adjuvant)
6 Completed Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Adults Unprimed and Primed With Adjuvanted or Non-adjuvanted Influenza Vaccines
Condition: Prophylaxis of Avian Influenza Vaccine
Intervention: Biological: Fluad H5N1 Pandemic Influenza Vaccine
7 Completed Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers
Conditions: Dengue;   Dengue Hemorrhagic Fever;   Yellow Fever
Interventions: Biological: Live, attenuated dengue serotype 1, 2, 3, and 4 virus;   Biological: Yellow fever vaccine;   Biological: Measles, mumps, and rubella vaccine;   Biological: Pneumococcal Conjugated Vaccine;   Biological: Hepatitis A Pediatric Vaccine;   Biological: Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae vaccine;   Biological: Yellow Fever Vaccine;   Biological: Placebo (NaCl)
8 Completed
Has Results
Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants
Conditions: Meningitis;   Meningococcal Infection
Interventions: Biological: MenACWY-CRM197;   Biological: DTaP (Diptheria, Tetanus, Pertussis) Vaccine;   Biological: Hib (Haemophilus influenza b) Vaccine;   Biological: IPV (Inactivated Polio Vaccine) Vaccine;   Biological: Pneumococcal conjugate Vaccine;   Biological: MMR (Measles, Mumps, and Rubella) Vaccine;   Biological: Varicella Vaccine;   Biological: Hepatitis A Virus
9 Completed Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules
Condition: Meningococcal Infections
Interventions: Biological: rMenB and concomitantly routine infant vaccinations;   Biological: rMenB and routine infant vaccinations;   Biological: Routine infant vaccines
10 Completed
Has Results
Clinical Study in Children, 6 Months to 3 Years of Age, to Assess Two Dose Levels of an Experimental Flu Vaccine, Using a Licensed Influenza Virus Vaccine, Vaxigrip® as the Control
Conditions: Influenza Vaccines;   Influenza Virus
Interventions: Biological: GSK Biologicals' influenza vaccine GSK1557482A;   Biological: Vaxigrip
11 Completed Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines
Conditions: Pneumococcal Disease;   Streptococcus Pneumoniae Vaccines
Interventions: Biological: Pneumococcal conjugate vaccine GSK1024850A;   Biological: Tritanrix-HepB;   Biological: Hiberix Hib vaccine;   Biological: Polio Sabin;   Biological: Poliorix;   Biological: Prevenar (Wyeth)
12 Completed
Has Results
Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines
Conditions: Hepatitis B;   Acellular Pertussis;   Tetanus;   Poliomyelitis;   Diphtheria
Interventions: Biological: Pneumococcal conjugate vaccine GSK1024850A;   Biological: Prevenar;   Biological: Infanrix hexa;   Biological: Infanrix IPV Hib;   Biological: Infanrix penta;   Biological: Infanrix IPV;   Biological: Meningitec;   Biological: NeisVac-C;   Biological: Menitorix
13 Active, not recruiting Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines in Adults
Condition: Influenza
Interventions: Biological: Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation),;   Biological: Fluzone® Intradermal Influenza Virus Vaccine (2013-2014 formulation),;   Biological: Fluzone® High Dose Influenza Virus Vaccine (2013-2014 formulation)
14 Completed
Has Results
Novartis Vaccine and Diagnostics Carriage Trial
Condition: N. Meningitidis Carriage
Interventions: Biological: Meningococcal B Recombinant + OMV vaccine (rMenB +OMV NZ);   Biological: MenACWY-CRM conjugate vaccine;   Biological: Japanese Encephalitis vaccine
15 Completed
Has Results
Safety and Immunogenicity of 3 Lots of Cell-derived Subunit Influenza Vaccine as Compared to 1 Lot to Egg-derived Subunit Influenza Vaccine in Healthy Adults (>=18 to <=60)
Condition: Influenza
Interventions: Biological: Cell-Derived Trivalent Subunit Influenza Vaccine Lot 1 (cTIV);   Biological: Cell-Derived Trivalent Subunit Influenza Vaccine Lot 2 (cTIV);   Biological: Cell-Derived Trivalent Subunit Influenza Vaccine Lot 3 (cTIV);   Biological: Egg-Derived Trivalent Subunit Influenza Vaccine (TIV)
16 Completed
Has Results
A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months
Condition: Meningococcal Disease
Interventions: Biological: MenACWY-CRM;   Biological: DTaP-IPV/Hib;   Biological: HBV;   Biological: PCV;   Biological: MMR
17 Completed
Has Results
Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received One or Four Doses of the Same Vaccine
Condition: Meningococcal Disease
Interventions: Biological: Meningococcal (group B) multicomponent recombinant adsorbed vaccine.;   Biological: Meningococcal (group B) multicomponent recombinant adsorbed vaccine, without Outer Membrane Vesicles (OMV)
18 Completed
Has Results
Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults
Condition: Pneumococcal Infections
Interventions: Biological: 13-valent pneumococcal conjugate vaccine (13vPnC);   Biological: 23-valent Pneumococcal Polysaccharide Vaccine (23vPS)
19 Completed
Has Results
Pediatric Safety and Immunogenicity Study of Cell-Culture Derived and Egg-based Subunit Influenza Vaccines in Healthy Children and Adolescents
Condition: Influenza
Interventions: Biological: Cell culture-derived influenza subunit vaccine (cTIV);   Biological: Egg derived influenza subunit vaccine (eTIV_f)
20 Completed Immunogenicity and Safety Following a Single Dose of Influenza Vaccines in Healthy Children Who Received Either One or the Other Vaccine (an Adjuvanted Sub-unit Influenza Vaccine and a Non-adjuvanted Split Virion Influenza Vaccine) in the Previous V70P2 Study
Condition: FLU
Intervention: Biological: Influenza Trivalent Inactivated Vaccines

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years